172 related articles for article (PubMed ID: 34905962)
1. Caution in Using the Activated Partial Thromboplastin Time to Monitor Argatroban in COVID-19 and Vaccine-Induced Immune Thrombocytopenia and Thrombosis (VITT).
Guy S; Kitchen S; Makris M; M Maclean R; Saccullo G; Vanveen JJ
Clin Appl Thromb Hemost; 2021; 27():10760296211066945. PubMed ID: 34905962
[TBL] [Abstract][Full Text] [Related]
2. Laboratory methods for monitoring argatroban in heparin-induced thrombocytopenia.
Guy S; Kitchen S; Hopkins B; Chunara Z; Stephenson-Brown A; van Veen JJ
Int J Lab Hematol; 2022 Apr; 44(2):399-406. PubMed ID: 34755452
[TBL] [Abstract][Full Text] [Related]
3. Limitation of the activated partial thromboplastin time as a monitoring method of the direct thrombin inhibitor argatroban.
Guy S; Kitchen S; Maclean R; Van Veen JJ
Int J Lab Hematol; 2015 Dec; 37(6):834-43. PubMed ID: 26305560
[TBL] [Abstract][Full Text] [Related]
4. GFHT proposals on the practical use of argatroban - With specifics regarding vaccine-induced immune thrombotic thrombocytopaenia (VITT).
Siguret V; Boissier E; De Maistre E; Gouin-Thibault I; James C; Lasne D; Mouton C; Godon A; Nguyen P; Lecompte T;
Anaesth Crit Care Pain Med; 2021 Dec; 40(6):100963. PubMed ID: 34673303
[TBL] [Abstract][Full Text] [Related]
5. Reducing harm associated with anticoagulation: practical considerations of argatroban therapy in heparin-induced thrombocytopenia.
Hursting MJ; Soffer J
Drug Saf; 2009; 32(3):203-18. PubMed ID: 19338378
[TBL] [Abstract][Full Text] [Related]
6. High-dose argatroban for treatment of heparin-induced thrombocytopenia with thrombosis: a case report and review of laboratory considerations.
Hellwig TR; Peitz GJ; Gulseth MP
Am J Health Syst Pharm; 2012 Mar; 69(6):490-5. PubMed ID: 22382479
[TBL] [Abstract][Full Text] [Related]
7. Argatroban therapy in heparin-induced thrombocytopenia with hepatic dysfunction.
Levine RL; Hursting MJ; McCollum D
Chest; 2006 May; 129(5):1167-75. PubMed ID: 16685006
[TBL] [Abstract][Full Text] [Related]
8. Effect of renal function on argatroban therapy in heparin-induced thrombocytopenia.
Guzzi LM; McCollum DA; Hursting MJ
J Thromb Thrombolysis; 2006 Dec; 22(3):169-76. PubMed ID: 17103051
[TBL] [Abstract][Full Text] [Related]
9. Argatroban therapy in women with heparin-induced thrombocytopenia.
Jang IK; Baron SJ; Hursting MJ; Anglade E
J Womens Health (Larchmt); 2007; 16(6):895-901. PubMed ID: 17678460
[TBL] [Abstract][Full Text] [Related]
10. Argatroban therapy for heparin-induced thrombocytopenia in ICU patients with multiple organ dysfunction syndrome: a retrospective study.
Saugel B; Phillip V; Moessmer G; Schmid RM; Huber W
Crit Care; 2010; 14(3):R90. PubMed ID: 20487559
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of argatroban and bivalirudine in patients with suspected heparin-induced thrombocytopenia.
Vo QA; Lin JK; Tong LM
Ann Pharmacother; 2015 Feb; 49(2):178-84. PubMed ID: 25515865
[TBL] [Abstract][Full Text] [Related]
12. Argatroban therapy for heparin-induced thrombocytopenia in acutely ill patients.
Gray A; Wallis DE; Hursting MJ; Katz E; Lewis BE
Clin Appl Thromb Hemost; 2007 Oct; 13(4):353-61. PubMed ID: 17911186
[TBL] [Abstract][Full Text] [Related]
13. Argatroban dosage requirements and outcomes in intensive care versus non-intensive care patients.
Smythe MA; Koerber JM; Forsyth LL; Priziola JL; Balasubramaniam M; Mattson JC
Pharmacotherapy; 2009 Sep; 29(9):1073-81. PubMed ID: 19698012
[TBL] [Abstract][Full Text] [Related]
14. Monitoring of Argatroban and Lepirudin: What is the Input of Laboratory Values in "Real Life"?
Seidel H; Kolde HJ
Clin Appl Thromb Hemost; 2018 Mar; 24(2):287-294. PubMed ID: 28320219
[TBL] [Abstract][Full Text] [Related]
15. Argatroban anticoagulation for heparin-induced thrombocytopenia in elderly patients.
Bartholomew JR; Pietrangeli CE; Hursting MJ
Drugs Aging; 2007; 24(6):489-99. PubMed ID: 17571914
[TBL] [Abstract][Full Text] [Related]
16. Heparin-induced thrombocytopenia in patients administered heparin solely for hemodialysis.
Murray PT; Hursting MJ
Ren Fail; 2006; 28(7):537-9. PubMed ID: 17050234
[TBL] [Abstract][Full Text] [Related]
17. Argatroban dosing of patients with heparin-induced thrombocytopenia and an elevated aPTT due to antiphospholipid antibody syndrome.
Pendleton R; Wheeler MM; Rodgers GM
Ann Pharmacother; 2006 May; 40(5):972-6. PubMed ID: 16569813
[TBL] [Abstract][Full Text] [Related]
18. Further evidence of the limitations of Activated Partial Thromboplastin Time to monitor Argatroban.
Guy S; Kitchen S; Van Veen JJ
Br J Haematol; 2018 Feb; 180(4):594-597. PubMed ID: 27785784
[No Abstract] [Full Text] [Related]
19. Effect of argatroban on the activated partial thromboplastin time: a comparison of 21 commercial reagents.
Francis JL; Hursting MJ
Blood Coagul Fibrinolysis; 2005 Jun; 16(4):251-7. PubMed ID: 15870544
[TBL] [Abstract][Full Text] [Related]
20. Monitoring Direct Thrombin Inhibitors With Calibrated Diluted Thrombin Time vs Activated Partial Thromboplastin Time in Pediatric Patients.
Hasan RA; Pak J; Kirk CJ; Friedland-Little JM; Chandler WL
Am J Clin Pathol; 2023 Jan; 159(1):60-68. PubMed ID: 36351044
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
